Although the potential for therapeutic gene transfer by replication-deficient Ad has resulted in extensive investigations of its toxicity and immunogenicity, less information is available on the ...

Adeno-associated virus (AAV) is an attractive gene delivery vector for human gene therapy. However, various issues remain to be overcome, including the requirement of high vector dose for clinically ...

Researchers report that they have determined the precise chemical structure of the HIV capsid, a protein shell that protects the virus's genetic material and is a key to its virulence. The capsid has ...

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced data on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV-1 capsid function, that ...

HIV, the virus that causes AIDS, has been studied extensively ever since the AIDS epidemic was officially recognized by health professionals in the early 1980s. During that time, research has led to ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, ...

Finding an effective, safe HIV vaccine is still an ongoing struggle for scientists, but a new, supercomputer-aided discovery is offering a new hope. Researchers from the University of Illinois and the ...

The nonprofit Finding Hope for Frizzle aims to initiate a clinical trial of the gene therapy for FRRS1L disease in the second half of 2026.

– Phase 1b Study Demonstrates Potent Antiviral Efficacy Following a Single Subcutaneous Injection of GS-6207, No Discontinuations Due to Adverse Events – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead ...